Cargando…

Systemic inflammation in COPD in relation to smoking status

BACKGROUND AND AIMS: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well...

Descripción completa

Detalles Bibliográficos
Autores principales: Serapinas, Danielius, Narbekovas, Andrius, Juskevicius, Jonas, Sakalauskas, Raimundas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463080/
https://www.ncbi.nlm.nih.gov/pubmed/22958407
http://dx.doi.org/10.1186/2049-6958-6-4-214
_version_ 1782245253903810560
author Serapinas, Danielius
Narbekovas, Andrius
Juskevicius, Jonas
Sakalauskas, Raimundas
author_facet Serapinas, Danielius
Narbekovas, Andrius
Juskevicius, Jonas
Sakalauskas, Raimundas
author_sort Serapinas, Danielius
collection PubMed
description BACKGROUND AND AIMS: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. MATERIALS AND METHODS: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. RESULTS: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p < 0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p < 0.05). CONCLUSIONS: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation.
format Online
Article
Text
id pubmed-3463080
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34630802012-10-04 Systemic inflammation in COPD in relation to smoking status Serapinas, Danielius Narbekovas, Andrius Juskevicius, Jonas Sakalauskas, Raimundas Multidiscip Respir Med Original Article BACKGROUND AND AIMS: Smoking is the main risk factor for the development of chronic obstructive pulmonary disease (COPD) that has been recently defined as a systemic pulmonary inflammatory disease. However, the impact of smoking itself on systemic inflammation in COPD patients has not yet been well established. The aim of our study was to investigate the association between inflammatory markers and smoking status. MATERIALS AND METHODS: We compared 202 current smokers, 61 ex-smokers and 57 never-smokers, all COPD patients. Assessments included medical history, spirometry, alpha-1 antitrypsin (AAT) genotyping, serum AAT, C-reactive protein (CRP), tumor necrosis factor (TNF)-α, and soluble tumor necrosis factor receptor (sTNFR)-1 and sTNFR-2 concentrations. RESULTS: AAT and CRP concentrations in smokers (1.75 ± 0.51 g/L and 14.4 [9.5-20.5] mg/L) and ex-smokers (1.69 ± 0.43 g/L and 12.3 [8.7-16.3] mg/L) were higher than in never-smokers (1.49 ± 0.38 g/L and 5.1 [2.5-8.7] mg/L; p < 0.05). sTNFR-1 level was higher in smokers than ex-smokers or never-smokers (241.2 pg/mL [145.3-349.4] vs. 213.7 pg/mL [147.1-280.3] and 205.2 pg/mL [125-275]; p < 0.05). CONCLUSIONS: Our data confirm that smoking is associated with increased levels of AAT, CRP, and sTNFR-1 in COPD patients, an array of systemic inflammation markers that continue to be active even after smoking cessation. BioMed Central 2011-08-31 /pmc/articles/PMC3463080/ /pubmed/22958407 http://dx.doi.org/10.1186/2049-6958-6-4-214 Text en Copyright ©2011 Novamedia srl
spellingShingle Original Article
Serapinas, Danielius
Narbekovas, Andrius
Juskevicius, Jonas
Sakalauskas, Raimundas
Systemic inflammation in COPD in relation to smoking status
title Systemic inflammation in COPD in relation to smoking status
title_full Systemic inflammation in COPD in relation to smoking status
title_fullStr Systemic inflammation in COPD in relation to smoking status
title_full_unstemmed Systemic inflammation in COPD in relation to smoking status
title_short Systemic inflammation in COPD in relation to smoking status
title_sort systemic inflammation in copd in relation to smoking status
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3463080/
https://www.ncbi.nlm.nih.gov/pubmed/22958407
http://dx.doi.org/10.1186/2049-6958-6-4-214
work_keys_str_mv AT serapinasdanielius systemicinflammationincopdinrelationtosmokingstatus
AT narbekovasandrius systemicinflammationincopdinrelationtosmokingstatus
AT juskeviciusjonas systemicinflammationincopdinrelationtosmokingstatus
AT sakalauskasraimundas systemicinflammationincopdinrelationtosmokingstatus